Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Hi EP - I hope you are right for my son's sake as well. Regards
https://www.globenewswire.com/news-release/2022/07/14/2479712/0/en/Summit-Therapeutics-Provides-Update-on-Ridinilazole.html
Well they might yet pull it off …
Thanks EP
It could well have a steep up turn … though quite on what news just now, I’ve not much of an idea
Onwards and upwards as FM used to say
Good to hear from you Chris, good luck with your current investment!
- EP
Hi EP & Ollie - So sorry to hear that you both held your investments I sold all my shares at $5 & got my money back.The writing on the wall for me was the curtailing of the trials.I am now in Harland & Wolff & now in as much trouble as with Summit.
I encouraged my son to Buy Summit & he never Sold so is also not in a good place.
I am not sure what the future is for Summit but they could turn it around & get above $6.
I wish you both good luck. Regards Chris
Quite. Hoping for a bounce now though a long way back to 6$ breakeven.
Hope you're keeping safe and well Ollieh
- EP
Didn't think I'd see it.
Held too long.
Yes, please bring on 15-20$ … please.
Hope those who are still reading here are well.
ATB - EP
Hi Ollieh - Agree not good news but there are clearly some benefits however I decided back in September to bail out as I was still in profit after having been invested for over 10 years.However I still keep a watching brief & await their next move.
https://www.marketwatch.com/investing/stock/smmt
Ridinilazole failed to show superiority to vancomycin, an old antibiotic used to treat C. difficile infections.
Long way back now I'm afraid.
Yes I get ya.
But hopefully going forward the fda may give summit some slack due to covid.
But in any case I'll wait out this trial .
Good luck .
Hi Ollieh - I was concerned with Summits risky decision saw the price dropping again the other week & Sold all my holdings at a small margin & have now invested in Harland & Wolff Group Holdings plc.
I may revisit Summit latter in the year but after investing since 2010 I felt it was time to get out over the years break even just.
https://www.fiercebiotech.com/biotech/fda-objects-to-summit-s-midstudy-pooling-pivotal-trials
'That bet has received a frosty reception from the FDA. “The FDA does not agree with the change to the primary endpoint that Summit proposed and has subsequently implemented in its ongoing phase 3 Ri-CoDIFy studies when combining the studies,” Summit said in a statement. '
Looks like covid will delay into next year.
News not far now .
HI, I bought about £10k of these in 2013 and forgot i had any in what became a dormant SIPP account.
Having found them today and realise they still have about £5k value, can someone give me an over view of what’s happened over the past few years? I was in when they were going through phase 2 for a DMD drug that ultimately didn’t live up to early promise but don’t know what’s happened with it since and what is expected.
Cheers
News not far away now.
Todays RNS:
Cambridge, MA, May 18, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today that it has selected a new preclinical candidate, SMT026738 (“SMT-738”), for development in the fight against multidrug resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. Simultaneously, Summit has received an award from CARB-X to progress this candidate through preclinical development and Phase 1a clinical trials. The award commits initial funding of up to $4.1 million, with the possibility of up to another $3.7 million based on the achievement of future milestones.
SMT-738 is the first of a novel class of precision antibiotics with a new mechanism of action that acts via the bacterial target, LolCDE. SMT-738 has the potential to treat multidrug resistant infections caused by a large family of pathogenic Gram-negative bacteria, the Enterobacteriaceae, that include serious human pathogens such as Escherichia coli and Klebsiella pneumoniae. Combining a novel antibiotic class (SMT-738) with a clinically unexploited target (LolCDE) mitigates the risk of pre-existing resistance, potentially allowing for the effective treatment of Enterobacteriaceae-caused infections that currently have very limited and failing treatment options due to resistance to existing antibiotic classes.
“Our mission at Summit is to create patient- and societal-friendly medicinal therapies that improve the quality and duration of patients’ lives, while resolving serious unmet needs,” said Robert W. Duggan, Executive Chairman and Chief Executive Officer of Summit. “SMT-738 has the potential to save the lives of patients with as yet untreatable infections through a novel drug class with a low propensity for resistance development. We are excited and optimistic to take on the real challenge of antibiotic resistance and are grateful to CARB-X for partnering with us in support of this important mission.”
SMT-738 was discovered using Summit’s proprietary technology, our Discuva Platform, as a part of the DDS-04 series, and we retain worldwide clinical development and commercial rights to the compound. We expect to begin Phase 1 studies in 2023.
“With the growing threat of antibiotic resistance, particularly with respect to CRE infections, SMT-738 is clearly differentiated from all agents, including the beta-lactamase inhibitors, that are currently used to treat such infections,” adds David Powell, Ph.D., Summit’s Chief Scientific Officer. “By leveraging the transposon libraries of bacteria within our Discuva Platform, we have identified the target to be the clinically unexploited LolCDE complex, an essential lipid transport system in Gram-negative bacteria. SMT-738 has potent in vitro activity against clinical CRE isolates including difficult to treat metallo-beta-lactamase carrying strains encoding the New Delhi Metallo-beta-lactamase (NDM). Having encountered no existing resistance in clinical isolates to the novel chemistry of S
Ment looking forward to 2nd half of 2021 for fda news.
Ok hadn't seen it ...Was wondering what was moving it north. Looking forward now to q2 now.
Bring on $15/$20
This was uploaded on LinkedIn Summit page over the weekend....
https://www.linkedin.com/posts/summit-plc_c-difficile-infection-summittxinccom-activity-6798986133368913920-tT_b
Hi Ollieh - The reason for the jump is Directors taking up their shares see link below to latest SEC listings -
https://www.nasdaq.com/market-activity/stocks/smmt/sec-filings
Edit: I am hoping the SP remains above $6.
Climbed up in after hours trading friday.
See if it reflects on open Monday.
But news in q2 anyway.
Hi Goldenegg - I had to hold when SP spiked for tax reasons but I am currently 50% down now but break even.With regards SP if trials successful then if there is a market compared with Vanc. then sky's the limit at least 2 to 3 times current SP maybe up to 5 times.Anyone's guess.
Had notice from Lloyds today. Have to declare your interest and have funds available by the 5th May.......